Hepatitis C Virus Infection: Discovery of Unexpected Proviral Effect of Guanylate-Binding Protein 1 (GBP1)

A research team from the Paul-Ehrlich-Institut has gained important insights into the role of the human guanylate-binding protein 1 (GBP1) in hepatitis C virus infection. Their results show that GBP1 performs a previously unknown function, that of a proviral factor, during the HCV life cycle. Contrary to previous assumptions, the protein does not inhibit infection, but promotes it. GBP1 is induced by treatment with interferons. Therefore this research, published in PLOS Pathogens, indicates that interferon-based therapies should take the different modes of action of immunoregulatory factors into account.

Background Research:

Hepatitis C is a viral infection that causes liver inflammation and damage. The infection is spread through contaminated blood, usually as a result of sharing needles or other equipment to inject drugs. Many people who are infected with Hepatitis C are not aware because they do not have any symptoms.

Guanylate-Binding Protein 1 (GBP1) belongs to the group of large GTPases, a group of enzymes whose actions help many cellular processes. Guanylate-Binding Proteins (GBPs) were initially identified as proteins induced by interferons, which are signaling proteins produced and released in response to pathogens such as viruses.

Interferon therapy was once the standard treatment for chronic Hepatitis C but it has now been largely replaced by direct-acting antiviral drugs. However, Interferons still have their place in certain areas of therapy due to their broad-spectrum antiviral effect.

The discovery made by Paul-Ehrlich-Institut researchers shows that GBP1 has an unexpected role in promoting HCV life cycle rather than inhibiting it.

FAQs:

Q: What is the significance of this research on Guanylate-Binding Protein 1 (GBP1)?
A: This research sheds light on the unexpected role GBP1 plays in promoting Hepatitis C Virus’ life cycle rather than inhibiting it as previously assumed.

Q: How does this affect current treatment methods for Hepatitis C?
A: The findings suggest that interferon-based therapies for HCV should consider the action mechanism difference between other immunoregulatory factors given that GBP1 is induced by Interferon treatments.

Q: What does proviral mean?
A: A provirus refers to a viral genome embedded within host DNA which can promote virus replication process; hence GBP1 acting “provirally” means supporting HCV lifecycle rather than blocking it.

Q: Does this new development imply Interferon treatment is not effective against Hepatitis C?
A: Not necessarily. Interferons may have broad-spectrum antiviral effects which can be useful in certain areas of therapy. However, it does look like treatments could potentially be improved by taking into account the GBP1 factor.

Q: What stages of HCV infection does GBP1 affect?
A: The research team’s observations indicate that GBP1 plays a role during the replication or assembly phase of the HCV life cycle.

Q: Is there possibility of development new drugs based on this discovery?
A: While it’s too early to say for sure, this discovery opens up potential avenues in drug development targeting new mechanisms for controlling or treating Hepatitis C.

Originamitteilung:

A research team from the Paul-Ehrlich-Institut has gained important insights into the role of the human guanylate-binding protein 1 (GBP1) in hepatitis C virus infection. Their results show that GBP1 performs a previously unknown function, that of a proviral factor, during the HCV life cycle. Contrary to previous assumptions, the protein does not inhibit infection, but promotes it. GBP1 is induced by treatment with interferons. Therefore this research, published in PLOS Pathogens, indicates that interferon-based therapies should take the different modes of action of immunoregulatory factors into account.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Multiresistente Keime in die Knie zwingen

Fluorierte Lipopeptide als hochwirksame Antibiotika
Multiresistente bakterielle Infektionen, gegen die keine bekannten Antibiotika mehr helfen, sind eine ernsthafte globale Bedrohung. Ein chinesisches Forschungsteam stellt in der Zeitschrift Angewandte Chemie jetzt einen Ansatz vor, auf dessen Basis sich neuartige Antibiotika gegen resistente Keime entwickeln lassen. Sie basieren auf Eiweißbausteinen mit fluorierten Lipidketten.

Read More